NCT04988945View on ClinicalTrials.gov

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2026

Conditions
HCC
Interventions
PROCEDURE

TACE

Procedure of TACE will be standardized.

RADIATION

SBRT

SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.

DRUG

Durvalumab

1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)

DRUG

Tremelimumab

300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.

Trial Locations (2)

Unknown

RECRUITING

Department of Surgery, The University of Hong Kong, Hong Kong

RECRUITING

The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER